Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (979)	2/4/2000 12:32:00 AM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 4474

OK, Mike I dug out the following from your post: biomednet.com HT1080 cells: a human fibrosarcoma cell line Further comments on traffic jams and distended ERs: - to date no effect in cultured cells - natural examples of ER-stored proteins are known - (ref/footnote 17 of paper) Aggregate-containing cells grow indefinitely (>180 doublings) at the same rate as control cells, implying that trafficking of a wide spectrum of critical proteins (including growth factor receptors and adhesion proteins) is functionally unaffected (unpublished data). Also, there was no reduction in the amount of protein stored over a 6-month period, indicating that retention of proteins in the ER is a stable phenotype. We also do not detect activation of the ER stress-sensing kinase PERK. PB (who is not telling how much he got for his MEDX shares bought at 4. no -g-)

To: Mike McFarland who wrote (979)	2/4/2000 11:52:00 AM
From: judge	Read Replies (1) \| Respond to of 4474

that is a great saying...

To: Mike McFarland who wrote (979)	2/4/2000 12:19:00 PM
From: LTK007	Read Replies (1) \| Respond to of 4474

Mike i have no position in ARIA just poking around,and i found this part of their press release to be noteworthy,in view that gene therapy was recently attacked vigorously on CBS-national news---and one agreesive lawyer has already filed one wrongful death suit using the devastating phrase "NASDAQ MEDICINE",and charged the gene therapy companies with wide spread suppression of "bad news" data. But ARIAD has addressed this straight on their press release,and is suggesting they are out side of that problem--BTW gene therapy death count now at least 4,now that Harvard has spoken up of their problems--if ARIAD has an edge here,think it would be quite significant <<But gene therapy is a tricky technology. It is hard to get cells to absorb the new genes, and sometimes they do not ``express,' or order the production of proteins, when they are supposed to. And there has been recent controversy over the death of an 18-year-old man as a result of gene therapy. Congress, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are investigating the case. Ariad chairman and chief executive officer Dr. Harvey Berger thinks his company's method is safer because it will use an adeno-associated virus (AAV) to carry the new genes into a patient's body. The viruses do not cause disease in humans>> max any thought on is ARIA still a buy at these levels?